Mousa S A, Schäfer M, Mitchell W M, Hassan A H, Stein C
Preclinical Pharmacology Laboratory, National Institute on Drug Abuse, NIH, Baltimore, MD 21224, USA.
Eur J Pharmacol. 1996 Sep 12;311(2-3):221-31. doi: 10.1016/0014-2999(96)00440-2.
Opioid peptides derived from immune cells produce analgesia by activating opioid receptors on peripheral sensory nerves in inflammation. Corticotropin-releasing hormone (CRH) and interleukin-1 beta (IL-1 beta) can release these opioids. Here we show that both corticotropin-releasing hormone and interleukin-1 beta elicit receptor-specific antinociception in inflamed paws of rats by an opioid-mediated mechanism. Autoradiographic studies demonstrate 125I-CRH and 125I-IL-1 beta binding sites on immune cells in lymph nodes and inflamed paws. This binding is of high affinity and displaceable by the respective unlabeled agonist and antagonist ligands but not by opioid or adrenergic compounds. 125I-CRH and 125I-IL-1 beta binding sites are absent on nerves and in non-inflamed subcutaneous tissue but their number is greatly enhanced in inflamed paws and lymph nodes. This upregulation of binding sites for the opioid-releasing agents corticotropin-releasing hormone and interleukin-1 beta likely represents part of the body's local response to combat inflammatory pain.
源自免疫细胞的阿片肽通过激活炎症状态下外周感觉神经上的阿片受体产生镇痛作用。促肾上腺皮质激素释放激素(CRH)和白细胞介素-1β(IL-1β)可释放这些阿片类物质。在此我们表明,促肾上腺皮质激素释放激素和白细胞介素-1β均通过阿片介导的机制在大鼠发炎的爪子中引发受体特异性抗伤害感受。放射自显影研究证明,在淋巴结和发炎爪子的免疫细胞上存在125I-CRH和125I-IL-1β结合位点。这种结合具有高亲和力,可被各自未标记的激动剂和拮抗剂配体取代,但不能被阿片类或肾上腺素能化合物取代。在神经和非发炎的皮下组织中不存在125I-CRH和125I-IL-1β结合位点,但在发炎的爪子和淋巴结中其数量大大增加。阿片释放剂促肾上腺皮质激素释放激素和白细胞介素-1β结合位点的这种上调可能代表了机体对抗炎症性疼痛的局部反应的一部分。